AgeX Therapeutics

AgeX Therapeutics is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West PhD initially as a subsidiary of BioTime Inc. with backing from British billionaire investor Jim Mellon and others.

West formerly served as CEO of BioTime and Advanced Cell Technology and founded Geron Corporation in 1990. The company’s vice president of new technology discovery is Aubrey de Grey PhD, who also serves as chief scientific officer of the SENS Research Foundation. The chairman is Gregory Bailey MD, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion.

Competitors include Alphabet Inc.’s Calico, Unity Biotechnology, and Samumed.


Aubrey de Grey

Aubrey David Nicholas Jasper de Grey is an English author and biomedical gerontologist. He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics Inc. He is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). He is known for his view that medical technology may enable human beings alive today not to die from age-related causes. He co-founded the Methuselah Foundation to support efforts in this direction.

De Grey is an international adjunct professor of the Moscow Institute of Physics and Technology, and a fellow of the Gerontological Society of America, the American Aging Association, and the Institute for Ethics and Emerging Technologies.

De Grey argues that most of the fundamental knowledge needed to develop effective anti-aging medicine already exists, and that the science is ahead of the funding. He works to identify and promote specific technological approaches to the reversal of various aspects of aging, or, as de Grey puts it, “… the set of accumulated side effects from metabolism that eventually kills us.”

MORE: Wikipedia